Global RNAi for Therapeutic Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 96

Report ID: 9318

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
At present, global expenses concentrates in US and Europe, US takes 80% market share and Europe takes 5% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in RNAi for Therapeutic) companies are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics. The five companies occupy about 83% of the market share.
In 2018, the global RNAi for Therapeutic market size was 990 million US$ and it is expected to reach 5200 million US$ by the end of 2025, with a CAGR of 23.1% during 2019-2025.

This report focuses on the global RNAi for Therapeutic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the RNAi for Therapeutic development in United States, Europe and China.

The key players covered in this study
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed

Market segment by Type, the product can be split into
siRNA
miRNA
shRNA

Market segment by Application, split into
Cancer
Cardiovascular
HBV
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global RNAi for Therapeutic status, future forecast, growth opportunity, key market and key players.
To present the RNAi for Therapeutic development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of RNAi for Therapeutic are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global RNAi for Therapeutic Market Size Growth Rate by Type (2014-2025)
1.4.2 siRNA
1.4.3 miRNA
1.4.4 shRNA
1.5 Market by Application
1.5.1 Global RNAi for Therapeutic Market Share by Application (2014-2025)
1.5.2 Cancer
1.5.3 Cardiovascular
1.5.4 HBV
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 RNAi for Therapeutic Market Size
2.2 RNAi for Therapeutic Growth Trends by Regions
2.2.1 RNAi for Therapeutic Market Size by Regions (2014-2025)
2.2.2 RNAi for Therapeutic Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 RNAi for Therapeutic Market Size by Manufacturers
3.1.1 Global RNAi for Therapeutic Revenue by Manufacturers (2014-2019)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2 RNAi for Therapeutic Key Players Head office and Area Served
3.3 Key Players RNAi for Therapeutic Product/Solution/Service
3.4 Date of Enter into RNAi for Therapeutic Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global RNAi for Therapeutic Market Size by Type (2014-2019)
4.2 Global RNAi for Therapeutic Market Size by Application (2014-2019)

5 United States
5.1 United States RNAi for Therapeutic Market Size (2014-2019)
5.2 RNAi for Therapeutic Key Players in United States
5.3 United States RNAi for Therapeutic Market Size by Type
5.4 United States RNAi for Therapeutic Market Size by Application

6 Europe
6.1 Europe RNAi for Therapeutic Market Size (2014-2019)
6.2 RNAi for Therapeutic Key Players in Europe
6.3 Europe RNAi for Therapeutic Market Size by Type
6.4 Europe RNAi for Therapeutic Market Size by Application

7 China
7.1 China RNAi for Therapeutic Market Size (2014-2019)
7.2 RNAi for Therapeutic Key Players in China
7.3 China RNAi for Therapeutic Market Size by Type
7.4 China RNAi for Therapeutic Market Size by Application

8 Japan
8.1 Japan RNAi for Therapeutic Market Size (2014-2019)
8.2 RNAi for Therapeutic Key Players in Japan
8.3 Japan RNAi for Therapeutic Market Size by Type
8.4 Japan RNAi for Therapeutic Market Size by Application

9 Southeast Asia
9.1 Southeast Asia RNAi for Therapeutic Market Size (2014-2019)
9.2 RNAi for Therapeutic Key Players in Southeast Asia
9.3 Southeast Asia RNAi for Therapeutic Market Size by Type
9.4 Southeast Asia RNAi for Therapeutic Market Size by Application

10 India
10.1 India RNAi for Therapeutic Market Size (2014-2019)
10.2 RNAi for Therapeutic Key Players in India
10.3 India RNAi for Therapeutic Market Size by Type
10.4 India RNAi for Therapeutic Market Size by Application

11 Central & South America
11.1 Central & South America RNAi for Therapeutic Market Size (2014-2019)
11.2 RNAi for Therapeutic Key Players in Central & South America
11.3 Central & South America RNAi for Therapeutic Market Size by Type
11.4 Central & South America RNAi for Therapeutic Market Size by Application

12 International Players Profiles
12.1 Alnylam Pharmaceuticals
12.1.1 Alnylam Pharmaceuticals Company Details
12.1.2 Company Description and Business Overview
12.1.3 RNAi for Therapeutic Introduction
12.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2014-2019)
12.1.5 Alnylam Pharmaceuticals Recent Development
12.2 Arbutus Biopharma (Tekmira)
12.2.1 Arbutus Biopharma (Tekmira) Company Details
12.2.2 Company Description and Business Overview
12.2.3 RNAi for Therapeutic Introduction
12.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2014-2019)
12.2.5 Arbutus Biopharma (Tekmira) Recent Development
12.3 Arrowhead
12.3.1 Arrowhead Company Details
12.3.2 Company Description and Business Overview
12.3.3 RNAi for Therapeutic Introduction
12.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2014-2019)
12.3.5 Arrowhead Recent Development
12.4 Dicerna Pharmaceuticals
12.4.1 Dicerna Pharmaceuticals Company Details
12.4.2 Company Description and Business Overview
12.4.3 RNAi for Therapeutic Introduction
12.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2014-2019)
12.4.5 Dicerna Pharmaceuticals Recent Development
12.5 Mirna Therapeutics
12.5.1 Mirna Therapeutics Company Details
12.5.2 Company Description and Business Overview
12.5.3 RNAi for Therapeutic Introduction
12.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2014-2019)
12.5.5 Mirna Therapeutics Recent Development
12.6 Quark Pharmaceuticals
12.6.1 Quark Pharmaceuticals Company Details
12.6.2 Company Description and Business Overview
12.6.3 RNAi for Therapeutic Introduction
12.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2014-2019)
12.6.5 Quark Pharmaceuticals Recent Development
12.7 RXi Pharmaceuticals
12.7.1 RXi Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 RNAi for Therapeutic Introduction
12.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2014-2019)
12.7.5 RXi Pharmaceuticals Recent Development
12.8 Silence Therapeutics
12.8.1 Silence Therapeutics Company Details
12.8.2 Company Description and Business Overview
12.8.3 RNAi for Therapeutic Introduction
12.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2014-2019)
12.8.5 Silence Therapeutics Recent Development
12.9 Benitec Biopharma
12.9.1 Benitec Biopharma Company Details
12.9.2 Company Description and Business Overview
12.9.3 RNAi for Therapeutic Introduction
12.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2014-2019)
12.9.5 Benitec Biopharma Recent Development
12.10 miRagen Therapeutics
12.10.1 miRagen Therapeutics Company Details
12.10.2 Company Description and Business Overview
12.10.3 RNAi for Therapeutic Introduction
12.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2014-2019)
12.10.5 miRagen Therapeutics Recent Development
12.11 Sylentis
12.12 Gradalis
12.13 Sirnaomics
12.14 Silenseed

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details